EPISODE · Nov 3, 2025 · 46 MIN
Ep. 7 - Heading to Houston: What We're Looking Forward to at ASN Kidney Week 2025 (with Dr. Pietro Canetta)
from Biotech Matters · host Jeff Fineberg, PhD and Pietro Canetta, MD
Bluestar is once again heading to ASN Kidney Week, this time in Houston, TX. Since our last episode, Otsuka, the manufacturer of sibeprenlimab, announced that the FDA has granted Priority Review of their BLA application; its PDUFA date is November 28th of this year. Additionally, Vera Therapeutics, the manufacturer of atacicept put out a press release this past summer that the ORIGIN Phase 3 trial met its primary endpoint of reduction in proteinuria (UPCR); participants receiving atacicept achieved a 46% reduction from baseline, and 42% reduction compared to placebo at week 36 (pth, 2026. After the 2023 conference, Dr. Pietro Canetta joined Bluestar Principal Jeff Fineberg on the Biotech Matters podcast to talk about all things IgAN, as well as the two FILSPARI trials and the data presented at the conference. So, it's only fitting that Dr. Canetta is back on the podcast to revisit that conversation, discuss what has happened in the two years since, and tell us what he's most looking forward to at this year's conference. Where to find Dr. Canetta: Columbia University Glomerular Center Where to learn more: Columbia CME Courses Glomerular Disease-Focused CME Course Topics and Timestamps 00:00 - Intro + recap 04:00 - Reflection on Filspari in FSGS; implications for UPCR in FSGS and other diseases going forward 12:40 - DKD: better/newer surrogate endpoints; matching patients to the right Tx 19:30 - IgAN: the 4-hit model of disease and the role of B cells 22:45 - Where do B cell-targeting therapies fit in the evolving IgAN Tx Paradigm? 26:45 - The counter argument to using Bcells early in IgAN treatment 30:10 - Bcells beyond IgAN: Lupus Nephritis and other glomerular diseases 33:00 - Different B cell-targeting mechanisms for different glomerular diseases and/or heterogeneous patient populations 36:45 - A homecoming for complement inhibitor therapies 42:00 - Other recommended sessions at Kidney Week 2025 45:00 - Where to learn more from Dr. Canetta
NOW PLAYING
Ep. 7 - Heading to Houston: What We're Looking Forward to at ASN Kidney Week 2025 (with Dr. Pietro Canetta)
No transcript for this episode yet
Similar Episodes
Jun 20, 2026 ·31m
Jun 20, 2026 ·24m
Jun 20, 2026 ·42m
Jun 20, 2026 ·26m
Jun 20, 2026 ·22m
Jun 20, 2026 ·37m